Arcturus Therapeutics Holdings Inc [ARCT] stock prices are up 9.59% to $21.25 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ARCT shares have gain 3.81% over the last week, with a monthly amount glided 17.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Scotiabank started tracking the stock with Sector Outperform rating on May 28, 2025, and set its price target to $32. On January 28, 2025, BTIG Research initiated with a Buy rating and assigned a price target of $41 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $70 on August 12, 2024. Canaccord Genuity initiated its recommendation with a Buy and recommended $90 as its price target on December 13, 2023. William Blair started tracking with a Outperform rating for this stock on July 24, 2023, and assigned it a price target of $71. In a note dated May 11, 2023, H.C. Wainwright upgraded an Buy rating on this stock and boosted its target price from $19 to $51.
The stock price of Arcturus Therapeutics Holdings Inc [ARCT] has been fluctuating between $8.04 and $23.59 over the past year. Currently, Wall Street analysts expect the stock to reach $43 within the next 12 months. Arcturus Therapeutics Holdings Inc [NASDAQ: ARCT] shares were valued at $21.25 at the most recent close of the market. An investor can expect a potential return of 102.35% based on the average ARCT price forecast.
Analyzing the ARCT fundamentals
The Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT] reported sales of 109.80M for trailing twelve months, representing a drop of -46.69%. Gross Profit Margin for this corporation currently stands at 0.45% with Operating Profit Margin at -0.62%, Pretax Profit Margin comes in at -0.51%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.25 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT]’s Current Ratio is 5.90. In addition, the Quick Ratio stands at 5.90 and the Cash Ratio stands at 4.22. Considering the valuation of this stock, the price to sales ratio is 5.26, the price to book ratio is 2.50.
